L&K Biomed Ltd. (KOSDAQ:156100)
South Korea · Delayed Price · Currency is KRW 7,100.00
+360.00 (5.34%)
At close: Oct 23, 2026
L&K Biomed Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 39,942 | 38,920 | 36,092 | 29,905 | 19,767 | 15,373 |
Revenue Growth | -0.11% | 7.84% | 20.69% | 51.28% | 28.59% | -20.58% |
Gross Profit Gross Profit Growth | 33,183 | 32,022 | 30,142 | 25,678 | 14,792 | 7,354 |
Operating Income Operating Income Growth | 338.96 | 715.12 | 3,078 | 2,034 | -12,738 | -15,280 |
Net Income Net Income Growth | 2,766 | -16,297 | 9,743 | -1,867 | -13,625 | -9,669 |
Earnings Per Share EPS Growth | 128.57 | -801.67 | 448.22 | -115.17 | -1017.14 | -722.29 |
EPS Growth | 45.09% | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
USA USA Growth | 26,269 | 26,184 | 24,594 | 21,824 | - | 10,294 |
South Korea South Korea Growth | 513.21 | 1,067 | 1,483 | 2,441 | 659.84 | 2,725 |
Thailand Thailand Growth | 6,747 | 5,552 | 4,121 | 2,489 | - | 895.19 |
Other Other Growth | 6,413 | 6,117 | 5,894 | 3,151 | - | 1,459 |
Total Total Growth | 39,942 | 38,920 | 36,092 | 29,905 | 19,767 | 15,373 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 21,249 | 6,286 | 19,943 | 12,776 | 13,003 | 19,216 |
Total Debt Total Debt Growth | 29,216 | 19,148 | 23,397 | 13,513 | 25,201 | 22,456 |
Net Cash (Debt) Net Cash Growth | -7,967 | -12,861 | -3,454 | -737.76 | -12,198 | -3,240 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -370.33 | -632.68 | -160.55 | -45.50 | -910.57 | -242.05 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -4,598 | -13,879 | -7,430 | -1,370 | -6,881 | -10,600 |
Capital Expenditures CapEx Growth | -4,919 | -2,991 | -584.84 | -2,047 | 196.74 | 98.75 |
Free Cash Flow Free Cash Flow Growth | -9,517 | -16,870 | -8,015 | -3,417 | -6,684 | -10,501 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 83.08% | 82.28% | 83.52% | 85.87% | 74.83% | 47.84% |
Operating Margin | 0.85% | 1.84% | 8.53% | 6.80% | -64.44% | -99.40% |
Pretax Margin | 4.54% | -44.05% | 27.19% | -21.63% | -82.45% | -57.88% |
Profit Margin | 6.93% | -41.87% | 27.00% | -6.24% | -68.93% | -62.90% |
FCF Margin | -23.83% | -43.34% | -22.21% | -11.43% | -33.81% | -68.31% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 55.22 | - | 13.57 | - | - | - |
Forward PE | - | 19.67 | 19.67 | 26.72 | 25.02 | 25.02 |
PS Ratio | 3.97 | 7.00 | 3.66 | 6.79 | 5.43 | 9.37 |